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Background: Profiling of the immune receptor repertoire is becoming increasingly relevant to the understanding
and clinical management of cancer, autoimmunity, aging, and infectious disease.
Findings: A platform technology is described that provides comprehensive immune receptor profiling.
Conclusion: Immunosequencing is a platform technology that allows the enumeration, specification and
quantification of each and every B-and/or T-cell in any biologic sample of interest. It is based on bias-controlled
multiplex PCR and high throughput sequencing and is highly accurate, standardized, and sensitive.Description of the technology
The adaptive immune system generates a remarkable
breadth of diversity in antigen-specific TCRs and Igs by
combinatorial recombination of gene segments in lym-
phocytes. The TCR is composed of two peptide chains,
encoded by the TCRA and TCRB or TCRG and TCRD
genes, respectively. There are thus two types of T-cell
receptors, αβ and γδ, that differ by the TCR heterodimer
type and immune function. The antigenic specificity of
T-cells is in large part determined by the amino acid se-
quence in the hypervariable complementarity-determining
region 3 (CDR3) regions of the T-cell receptors. The exist-
ence of multiple V and J gene segments at these T-cell loci
permits a large combinatorial diversity in receptor com-
position; and the non-templated insertion or deletion of
nucleotides at the V-J, V-D, and D-J junctions further adds
to the potential diversity of receptors that can be encoded.
Because of the potential diversity of receptors it is highly
improbable to randomly converge on the same TCRB
nucleotide CDR3 sequence, effectively making each CDR3
sequence a unique tag for a T-cell clone.
Immunosequencing is a multiplex PCR-based based
method that amplifies rearranged TCR CDR3 sequences
for a given TCR locus (Fig. 1) and exploits the capacity
of high-throughput sequencing (HTS) technology to
characterize tens of thousands of TCR CDR3 chains
simultaneously. The technology can be applied to cDNA
or genomic DNA, but when it utilizes genomic DNA,Correspondence: lkirsch@adaptivebiotech.com
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sentative of the relative frequency of each T-cell contain-
ing CDR3 sequence in the biologic sample. Thus, this
assay captures both the full TCR repertoire and specific
individual clones. Given the capacity of HTS, this assay
is extremely sensitive and only limited by the amount of
DNA that is analyzed. Routinely, if one million cells’
worth of DNA is analyzed the assay can detect clones at
sensitivity that approaches 1:1,000,000. This is about
100-fold greater than current detection methods (e.g.,
flow cytometry) and less subject to the occurrence of
“false positive” and “false negative” results than TCR
PCR. The technology provides a highly accurate and
standardized method for assessment of lymphoid clonal-
ity in healthy, diseased, or malignant tissues and for
identification and tracking the presence and frequency
of common and rare clones within the total adaptive
immune system.Type of data obtained/readout
For each sample, DNA is extracted and the relevant im-
mune receptor CDR3 regions amplified and sequenced.
Bias-controlled V and J gene primers are used to amplify
rearranged V(D)J segments for high throughput sequen-
cing at ~10 × coverage. Raw sequence data is uploaded
and after correcting sequencing errors via a clustering
algorithm, primary nucleotide sequence of the amplified
regions from the immune receptors’ unique CDR3 seg-
ments are identified, quantified, and annotated accord-
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Fig. 1 TCRB sequencing assay. a Multiple V, D and J segments exist
in the germline genome, non-templated diversity is introduced at
the junctions by insertion of random nucleotides (shown as N) b The
assay uses a multiplex PCR with forward primers in each V segment
and reverse primers in each J segment
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rearrangement.Limitations of the approach
In isolation, immunosequencing only provides informa-
tion relevant to the enumeration, specification, and
quantification of each and every B-and/or T-cell in a
given sample of interest. It can be combined with other
technologies focused on immunophenotypic characte-
rization or single cell isolation to provide more compre-
hensive information on the physiologic and developmental
status of the individual cells or populations.Types of samples needed and special issues
pertaining to samples
The assay is capable of providing information from
fresh, frozen, or FFPE samples and has been tested on
blood, bone marrow, lymph node, spleen, kidney, liver,
lung, brain, ovary, skin, cell-free DNA, primary and
metastatic tumor and other tissues.Level of evidence
Approximately 100 manuscripts and poster presentations
have been published using this platform. The analytic
validity, clinical validity, and clinical utility is presented in
many of these publications (see for example, refs [1–7]).
The process is conducted in CLIA and CAP certified
laboratories. An RUO kit is also available.
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